KalVista Q3 2022 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the third fiscal quarter ended January 31, 2022. The net loss was $22.5 million, or $(0.92) per share. Research and development expenses were $19.7 million, and general and administrative expenses were $6.9 million. Cash, cash equivalents, and marketable securities totaled $194.8 million as of January 31, 2022.
Initiated the Phase 3 clinical trial of KVD900 (KONFIDENT) for on-demand treatment of HAE attacks.
Continued enrollment in the Phase 2 clinical trial of KVD824 (KOMPLETE) for HAE prophylaxis, with data expected in mid-2023.
Presented data for KVD900 at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting.
Made continued progress in the Factor XIIa inhibitor program, with an expected first IND for an oral Factor XIIa inhibitor candidate in 2023.